{"id":867629,"date":"2025-07-08T16:20:13","date_gmt":"2025-07-08T20:20:13","guid":{"rendered":"https:\/\/www.marketnewsdesk.com\/index.php\/tyra-biosciences-announces-late-breaking-poster-presentation-on-tyra-300-preclinical-results-at-endo-2025\/"},"modified":"2025-07-08T16:20:13","modified_gmt":"2025-07-08T20:20:13","slug":"tyra-biosciences-announces-late-breaking-poster-presentation-on-tyra-300-preclinical-results-at-endo-2025","status":"publish","type":"post","link":"https:\/\/www.marketnewsdesk.com\/index.php\/tyra-biosciences-announces-late-breaking-poster-presentation-on-tyra-300-preclinical-results-at-endo-2025\/","title":{"rendered":"Tyra Biosciences Announces Late-Breaking Poster Presentation on TYRA-300 Preclinical Results at ENDO 2025"},"content":{"rendered":"<div class=\"xn-newslines\">\n<p class=\"xn-distributor\">PR Newswire<\/p>\n<\/p><\/div>\n<div class=\"xn-content\">\n<p>\n        <span class=\"legendSpanClass\"><br \/>\n          <span class=\"xn-location\">CARLSBAD, Calif.<\/span><br \/>\n        <\/span>, <span class=\"legendSpanClass\"><span class=\"xn-chron\">July 8, 2025<\/span><\/span> \/PRNewswire\/ &#8212;\u00a0Tyra Biosciences, Inc.\u00a0(Nasdaq: TYRA), a clinical-stage biotechnology company focused on developing next-generation precision medicines that target large opportunities in Fibroblast Growth Factor Receptor (FGFR) biology, announced today that a late-breaking abstract has been accepted for presentation at The Endocrine Society&#8217;s Annual Meeting (ENDO 2025), taking place <span class=\"xn-chron\">July 12-15, 2025<\/span> in <span class=\"xn-location\">San Francisco, CA.<\/span><\/p>\n<p>Details of the poster presentation are below:<\/p>\n<ul type=\"disc\">\n<li>Title: &#8220;<i>TYRA-300 Promotes Bone Growth In Two Mouse Models Of FGFR3-related Skeletal Dysplasia<\/i>&#8220;<\/li>\n<li>Abstract: SUN-730<\/li>\n<li>Presenting Author: <span class=\"xn-person\">Jacqueline H. Starrett<\/span>, Ph.D., Tyra Biosciences<\/li>\n<li>Date\/Time: <span class=\"xn-chron\">July 13, 2025<\/span>, <span class=\"xn-chron\">12:00 PM &#8211; 1:30 PM<\/span>, ENDOExpo: Poster Area<\/li>\n<li>Session: Session P70 &#8211; BONE AND MINERAL METABOLISM: Rare Bone and Genetic Disorders<\/li>\n<\/ul>\n<p>More information on ENDO 2025 can be found at the meeting website. The\u00a0TYRA poster at ENDO 2025 will be available here following the conference: <a href=\"https:\/\/c212.net\/c\/link\/?t=0&amp;l=en&amp;o=4463430-1&amp;h=698462177&amp;u=https%3A%2F%2Furl.avanan.click%2Fv2%2F___https%3A%2Fir.tyra.bio___.YXAzOnR5cmExOmE6bzo4YTFmODMzMTkxOTkxYzRjZWQ2Y2NhODFiMmFiNTNmMTo2OmQ1ZTI6MDQxODk1NjBkNGI0MmZiZTk0ZWEyMzk5MzQ5ZGZjM2ZjYzY0ODBkYWU1OWFhZDRhMDBhZGU0NGVkZDllMGM5NDpwOlQ6Rg&amp;a=https%3A%2F%2Fir.tyra.bio\" target=\"_blank\" rel=\"nofollow\">https:\/\/ir.tyra.bio<\/a>.<\/p>\n<p>\n        <b>About TYRA-300<\/b>\n      <\/p>\n<p>TYRA-300 is the Company&#8217;s lead precision medicine program stemming from its in-house SN\u00c5P platform. TYRA-300 is an investigational, oral, FGFR3-selective inhibitor currently in development for the treatment of cancer and skeletal dysplasia that has demonstrated interim clinical proof-of-concept results in metastatic urothelial cancer (mUC). TYRA-300&#8217;s planned clinical development includes three Phase 2 clinical trials: SURF302 for intermediate risk non-muscle invasive bladder cancer (IR NMIBC), BEACH301 for pediatric achondroplasia and SURF301 for mUC.\u00a0<\/p>\n<p>Please visit the\u00a0<a href=\"https:\/\/c212.net\/c\/link\/?t=0&amp;l=en&amp;o=4463430-1&amp;h=42179760&amp;u=https%3A%2F%2Furl.avanan.click%2Fv2%2F___https%3A%2Fc212.net%2Fc%2Flink%2F%3Ft%3D0%26l%3Den%26o%3D4459316-1%26h%3D271309998%26u%3Dhttps%253A%252F%252Furl.avanan.click%252Fv2%252F___https%253A%252Ftyra.bio%252Fpatients%252F___.YXAzOnR5cmExOmE6bzo1YWMwYTRiNDhiNjhhZWNlNjBiZGNkNzQ3NjMwOWE0OTo2OjNiNjc6NmZkMjYwN2VhZDIxMjdiNzI0Nzc2ODYxN2M0YjNiYzdhMDRlZjBhNmY0MjE0NzdmMWI1NzQ5YmIyN2YxM2ZmYTpwOlQ6Rg%26a%3DPatients___.YXAzOnR5cmExOmE6bzo4YTFmODMzMTkxOTkxYzRjZWQ2Y2NhODFiMmFiNTNmMTo2OmM3YjM6MGZkZGU5NmRkODQ1OTRkZTQyNDc0MTYyOGU2ZjE4ZDA2YTg2ODBkMzMzZjBjYWI0NWE0Mzg2M2M5YzE1OGM3OTpwOlQ6Rg&amp;a=Patients\" target=\"_blank\" rel=\"nofollow\"><b>Patients<\/b><\/a>\u00a0page of our website for more information on our clinical trials.<\/p>\n<p>\n        <b>About\u00a0Tyra Biosciences<\/b>\n      <\/p>\n<p>Tyra Biosciences, Inc.\u00a0(Nasdaq: TYRA) is a clinical-stage biotechnology company focused on developing next-generation precision medicines that target large opportunities in FGFR biology. The Company&#8217;s in-house precision medicine platform, SN\u00c5P, enables rapid and precise drug design through iterative molecular SN\u00c5Pshots that help predict genetic alterations most likely to cause acquired resistance to existing therapies. TYRA&#8217;s expertise in FGFR biology has created a differentiated pipeline with three clinical-stage programs in targeted oncology and genetically defined conditions. The Company&#8217;s lead precision medicine stemming from\u00a0SN\u00c5P, TYRA-300, is a potential first-in-class selective FGFR3 inhibitor that is designed to avoid the toxicities associated with inhibition of FGFR1, FGFR2 and FGFR4, while being agnostic for FGFR3 gatekeeper mutations. TYRA-300&#8217;s planned clinical development includes three Phase 2 studies: SURF302 for IR NMIBC, BEACH301 for pediatric achondroplasia and SURF301 for mUC. TYRA is also developing TYRA-200, an oral, investigational, FGFR1\/2\/3 inhibitor, in the SURF201 study for metastatic intrahepatic cholangiocarcinoma, and TYRA-430, an oral, investigational FGFR4\/3-biased inhibitor for FGF19+\/FGFR4-driven cancers. TYRA is based in\u00a0Carlsbad, CA.<\/p>\n<p>For more information about our science, pipeline and people, please visit\u00a0<a href=\"https:\/\/c212.net\/c\/link\/?t=0&amp;l=en&amp;o=4463430-1&amp;h=307522540&amp;u=https%3A%2F%2Furl.avanan.click%2Fv2%2F___https%3A%2Fc212.net%2Fc%2Flink%2F%3Ft%3D0%26l%3Den%26o%3D4459316-1%26h%3D2215562391%26u%3Dhttps%253A%252F%252Furl.avanan.click%252Fv2%252F___https%253A%252Fc212.net%252Fc%252Flink%252F%253Ft%253D0%2526l%253Den%2526o%253D4337815-1%2526h%253D651663154%2526u%253Dhttps%25253A%25252F%25252Furl.avanan.click%25252Fv2%25252F___http%25253A%25252Fwww.tyra.bio___.YXAzOnR5cmExOmE6bzo5OTg0OTgwMGE1ZDdlYTIxMjM5ZTRmZjg2NzVmMGE1MTo2OjQ1ODA6MzY0YmE4ZTc0NGQyYWZiZWFjZTJkZTBjMTE5M2RlN2Q0YjZlZGQzMDAwMTQ3MGFhZjAzYzU0NmI1NjI0ZDFjMDpwOlQ6Rg%2526a%253Dwww.tyra.bio___.YXAzOnR5cmExOmE6bzpkN2IwZWE2ZTZhMDQ5NWI4OWQ3MTY3Njc0YTUyZTI3Mzo2OmZjMWM6ZDc3MDJiMmRlM2UxMGRjOWQ5OTU4ZmE5OTQ1N2VkZDY2YjRjNmJlNzU2ZDNkZmEzYzgyZDNhYjU4YzE4NDE4YjpwOlQ6Rg%26a%3Dwww.tyra.bio___.YXAzOnR5cmExOmE6bzo4YTFmODMzMTkxOTkxYzRjZWQ2Y2NhODFiMmFiNTNmMTo2Ojg4Yjk6MzNlYTRiZGNlYmZlNTE0OTk1ZGRkZDU4MjBkNmZjZmM1ZWI2OTdiYjhjZTNmNWU1ODRjY2Q1M2M3YzE0MTI0NjpwOlQ6Rg&amp;a=www.tyra.bio\" target=\"_blank\" rel=\"nofollow\"><b>www.tyra.bio<\/b><\/a>\u00a0and engage with us on\u00a0<a href=\"https:\/\/c212.net\/c\/link\/?t=0&amp;l=en&amp;o=4463430-1&amp;h=3300070426&amp;u=https%3A%2F%2Furl.avanan.click%2Fv2%2F___https%3A%2Fc212.net%2Fc%2Flink%2F%3Ft%3D0%26l%3Den%26o%3D4459316-1%26h%3D3435229399%26u%3Dhttps%253A%252F%252Furl.avanan.click%252Fv2%252F___https%253A%252Fc212.net%252Fc%252Flink%252F%253Ft%253D0%2526l%253Den%2526o%253D4337815-1%2526h%253D2860849053%2526u%253Dhttps%25253A%25252F%25252Furl.avanan.click%25252Fv2%25252F___https%25253A%25252Fwww.linkedin.com%25252Fcompany%25252Ftyra-biosciences%25252F%25253FviewAsMember%25253Dtrue___.YXAzOnR5cmExOmE6bzo5OTg0OTgwMGE1ZDdlYTIxMjM5ZTRmZjg2NzVmMGE1MTo2OjJiNWQ6NWQwYTE0ZTczYjg2NDg4ZTZhNzBhNGE1N2VkNzNhMTYyYTI3NGFlM2EwYjc5MWRmZjY5NGQzMjNjMjYyNmUyNjpwOlQ6Rg%2526a%253DLinkedIn___.YXAzOnR5cmExOmE6bzpkN2IwZWE2ZTZhMDQ5NWI4OWQ3MTY3Njc0YTUyZTI3Mzo2OjAyYTM6MzE2M2M2N2Y0ZjQ3MzA0MDczZTFjZTk5OTFkMGQxMjg4NTgyN2M4OTNlZDIxZjJjMDFkNTdhZDhhN2NkOWNmYzpwOlQ6Rg%26a%3DLinkedIn___.YXAzOnR5cmExOmE6bzo4YTFmODMzMTkxOTkxYzRjZWQ2Y2NhODFiMmFiNTNmMTo2OjY0MzE6MTA3ODcxMjRjOTBiNzg1NTI1M2RiZjY4NWI3Y2UyYjNjZThkMTQyNmUxNTdkN2EwYTRlYmRkNDEwZmRmZmY5NDpwOlQ6Rg&amp;a=LinkedIn\" target=\"_blank\" rel=\"nofollow\"><b>LinkedIn<\/b><\/a>.<\/p>\n<p>\n        <b>Contact:<\/b><br \/>\n        <br \/>\n        <span class=\"xn-person\">Amy Conrad<\/span><br \/>\n        <br \/>\n        <a href=\"mailto:aconrad@tyra.bio\" target=\"_blank\" rel=\"nofollow\">aconrad@tyra.bio<\/a>\n      <\/p>\n<div class=\"PRN_ImbeddedAssetReference\" id=\"DivAssetPlaceHolder3974\">\n<p>\n          <a href=\"https:\/\/mma.prnewswire.com\/media\/1626125\/Tyra_Logo.html\" target=\"_blank\" rel=\"nofollow\"><br \/>\n            <img decoding=\"async\" src=\"https:\/\/mma.prnewswire.com\/media\/1626125\/Tyra_Logo.jpg\" title=\"(PRNewsfoto\/Tyra Biosciences, Inc.)\" alt=\"(PRNewsfoto\/Tyra Biosciences, Inc.)\" \/><br \/>\n          <\/a>\n        <\/p>\n<\/p><\/div>\n<div class=\"PRN_ImbeddedAssetReference\" id=\"DivAssetPlaceHolder0\"><\/div>\n<p id=\"PURL\">\n        <img loading=\"lazy\" decoding=\"async\" title=\"Cision\" width=\"12\" height=\"12\" alt=\"Cision\" src=\"https:\/\/c212.net\/c\/img\/favicon.png?sn=LA25235&amp;sd=2025-07-08\" \/> View original content to download multimedia:<a id=\"PRNURL\" rel=\"nofollow\" href=\"https:\/\/www.prnewswire.com\/news-releases\/tyra-biosciences-announces-late-breaking-poster-presentation-on-tyra-300-preclinical-results-at-endo-2025-302500095.html\" target=\"_blank\">https:\/\/www.prnewswire.com\/news-releases\/tyra-biosciences-announces-late-breaking-poster-presentation-on-tyra-300-preclinical-results-at-endo-2025-302500095.html<\/a><\/p>\n<p>SOURCE  Tyra Biosciences<\/p>\n<\/p><\/div>\n<p>    <img decoding=\"async\" alt=\"\" src=\"https:\/\/rt.prnewswire.com\/rt.gif?NewsItemId=LA25235&amp;Transmission_Id=202507081605PR_NEWS_USPR_____LA25235&amp;DateId=20250708\" style=\"border:0px;width:1px;height:1px\" \/><\/p>\n","protected":false},"excerpt":{"rendered":"<p>PR Newswire CARLSBAD, Calif. , July 8, 2025 \/PRNewswire\/ &#8212;\u00a0Tyra Biosciences, Inc.\u00a0(Nasdaq: TYRA), a clinical-stage biotechnology company focused on developing next-generation precision medicines that target large opportunities in Fibroblast Growth Factor Receptor (FGFR) biology, announced today that a late-breaking abstract has been accepted for presentation at The Endocrine Society&#8217;s Annual Meeting (ENDO 2025), taking place July 12-15, 2025 in San Francisco, CA. Details of the poster presentation are below: Title: &#8220;TYRA-300 Promotes Bone Growth In Two Mouse Models Of FGFR3-related Skeletal Dysplasia&#8220; Abstract: SUN-730 Presenting Author: Jacqueline H. Starrett, Ph.D., Tyra Biosciences Date\/Time: July 13, 2025, 12:00 PM &#8211; 1:30 PM, ENDOExpo: Poster Area Session: Session P70 &#8211; BONE AND MINERAL METABOLISM: Rare Bone and Genetic Disorders More information on &hellip; <\/p>\n<p class=\"link-more\"><a href=\"https:\/\/www.marketnewsdesk.com\/index.php\/tyra-biosciences-announces-late-breaking-poster-presentation-on-tyra-300-preclinical-results-at-endo-2025\/\" class=\"more-link\">Continue reading<span class=\"screen-reader-text\"> &#8220;Tyra Biosciences Announces Late-Breaking Poster Presentation on TYRA-300 Preclinical Results at ENDO 2025&#8221;<\/span><\/a><\/p>\n","protected":false},"author":2,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[],"tags":[],"class_list":["post-867629","post","type-post","status-publish","format-standard","hentry"],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v27.4 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>Tyra Biosciences Announces Late-Breaking Poster Presentation on TYRA-300 Preclinical Results at ENDO 2025 - Market Newsdesk<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.marketnewsdesk.com\/index.php\/tyra-biosciences-announces-late-breaking-poster-presentation-on-tyra-300-preclinical-results-at-endo-2025\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Tyra Biosciences Announces Late-Breaking Poster Presentation on TYRA-300 Preclinical Results at ENDO 2025 - Market Newsdesk\" \/>\n<meta property=\"og:description\" content=\"PR Newswire CARLSBAD, Calif. , July 8, 2025 \/PRNewswire\/ &#8212;\u00a0Tyra Biosciences, Inc.\u00a0(Nasdaq: TYRA), a clinical-stage biotechnology company focused on developing next-generation precision medicines that target large opportunities in Fibroblast Growth Factor Receptor (FGFR) biology, announced today that a late-breaking abstract has been accepted for presentation at The Endocrine Society&#8217;s Annual Meeting (ENDO 2025), taking place July 12-15, 2025 in San Francisco, CA. Details of the poster presentation are below: Title: &#8220;TYRA-300 Promotes Bone Growth In Two Mouse Models Of FGFR3-related Skeletal Dysplasia&#8220; Abstract: SUN-730 Presenting Author: Jacqueline H. Starrett, Ph.D., Tyra Biosciences Date\/Time: July 13, 2025, 12:00 PM &#8211; 1:30 PM, ENDOExpo: Poster Area Session: Session P70 &#8211; BONE AND MINERAL METABOLISM: Rare Bone and Genetic Disorders More information on &hellip; Continue reading &quot;Tyra Biosciences Announces Late-Breaking Poster Presentation on TYRA-300 Preclinical Results at ENDO 2025&quot;\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.marketnewsdesk.com\/index.php\/tyra-biosciences-announces-late-breaking-poster-presentation-on-tyra-300-preclinical-results-at-endo-2025\/\" \/>\n<meta property=\"og:site_name\" content=\"Market Newsdesk\" \/>\n<meta property=\"article:published_time\" content=\"2025-07-08T20:20:13+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/mma.prnewswire.com\/media\/1626125\/Tyra_Logo.jpg\" \/>\n<meta name=\"author\" content=\"Newsdesk\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Newsdesk\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"2 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/tyra-biosciences-announces-late-breaking-poster-presentation-on-tyra-300-preclinical-results-at-endo-2025\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/tyra-biosciences-announces-late-breaking-poster-presentation-on-tyra-300-preclinical-results-at-endo-2025\\\/\"},\"author\":{\"name\":\"Newsdesk\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"headline\":\"Tyra Biosciences Announces Late-Breaking Poster Presentation on TYRA-300 Preclinical Results at ENDO 2025\",\"datePublished\":\"2025-07-08T20:20:13+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/tyra-biosciences-announces-late-breaking-poster-presentation-on-tyra-300-preclinical-results-at-endo-2025\\\/\"},\"wordCount\":464,\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/tyra-biosciences-announces-late-breaking-poster-presentation-on-tyra-300-preclinical-results-at-endo-2025\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/mma.prnewswire.com\\\/media\\\/1626125\\\/Tyra_Logo.jpg\",\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/tyra-biosciences-announces-late-breaking-poster-presentation-on-tyra-300-preclinical-results-at-endo-2025\\\/\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/tyra-biosciences-announces-late-breaking-poster-presentation-on-tyra-300-preclinical-results-at-endo-2025\\\/\",\"name\":\"Tyra Biosciences Announces Late-Breaking Poster Presentation on TYRA-300 Preclinical Results at ENDO 2025 - Market Newsdesk\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/tyra-biosciences-announces-late-breaking-poster-presentation-on-tyra-300-preclinical-results-at-endo-2025\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/tyra-biosciences-announces-late-breaking-poster-presentation-on-tyra-300-preclinical-results-at-endo-2025\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/mma.prnewswire.com\\\/media\\\/1626125\\\/Tyra_Logo.jpg\",\"datePublished\":\"2025-07-08T20:20:13+00:00\",\"author\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"breadcrumb\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/tyra-biosciences-announces-late-breaking-poster-presentation-on-tyra-300-preclinical-results-at-endo-2025\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/tyra-biosciences-announces-late-breaking-poster-presentation-on-tyra-300-preclinical-results-at-endo-2025\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/tyra-biosciences-announces-late-breaking-poster-presentation-on-tyra-300-preclinical-results-at-endo-2025\\\/#primaryimage\",\"url\":\"https:\\\/\\\/mma.prnewswire.com\\\/media\\\/1626125\\\/Tyra_Logo.jpg\",\"contentUrl\":\"https:\\\/\\\/mma.prnewswire.com\\\/media\\\/1626125\\\/Tyra_Logo.jpg\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/tyra-biosciences-announces-late-breaking-poster-presentation-on-tyra-300-preclinical-results-at-endo-2025\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Tyra Biosciences Announces Late-Breaking Poster Presentation on TYRA-300 Preclinical Results at ENDO 2025\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\",\"name\":\"Market Newsdesk\",\"description\":\"Latest Business News in Real Time\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\",\"name\":\"Newsdesk\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"caption\":\"Newsdesk\"},\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/author\\\/newsdesk\\\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Tyra Biosciences Announces Late-Breaking Poster Presentation on TYRA-300 Preclinical Results at ENDO 2025 - Market Newsdesk","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.marketnewsdesk.com\/index.php\/tyra-biosciences-announces-late-breaking-poster-presentation-on-tyra-300-preclinical-results-at-endo-2025\/","og_locale":"en_US","og_type":"article","og_title":"Tyra Biosciences Announces Late-Breaking Poster Presentation on TYRA-300 Preclinical Results at ENDO 2025 - Market Newsdesk","og_description":"PR Newswire CARLSBAD, Calif. , July 8, 2025 \/PRNewswire\/ &#8212;\u00a0Tyra Biosciences, Inc.\u00a0(Nasdaq: TYRA), a clinical-stage biotechnology company focused on developing next-generation precision medicines that target large opportunities in Fibroblast Growth Factor Receptor (FGFR) biology, announced today that a late-breaking abstract has been accepted for presentation at The Endocrine Society&#8217;s Annual Meeting (ENDO 2025), taking place July 12-15, 2025 in San Francisco, CA. Details of the poster presentation are below: Title: &#8220;TYRA-300 Promotes Bone Growth In Two Mouse Models Of FGFR3-related Skeletal Dysplasia&#8220; Abstract: SUN-730 Presenting Author: Jacqueline H. Starrett, Ph.D., Tyra Biosciences Date\/Time: July 13, 2025, 12:00 PM &#8211; 1:30 PM, ENDOExpo: Poster Area Session: Session P70 &#8211; BONE AND MINERAL METABOLISM: Rare Bone and Genetic Disorders More information on &hellip; Continue reading \"Tyra Biosciences Announces Late-Breaking Poster Presentation on TYRA-300 Preclinical Results at ENDO 2025\"","og_url":"https:\/\/www.marketnewsdesk.com\/index.php\/tyra-biosciences-announces-late-breaking-poster-presentation-on-tyra-300-preclinical-results-at-endo-2025\/","og_site_name":"Market Newsdesk","article_published_time":"2025-07-08T20:20:13+00:00","og_image":[{"url":"https:\/\/mma.prnewswire.com\/media\/1626125\/Tyra_Logo.jpg","type":"","width":"","height":""}],"author":"Newsdesk","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Newsdesk","Est. reading time":"2 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/tyra-biosciences-announces-late-breaking-poster-presentation-on-tyra-300-preclinical-results-at-endo-2025\/#article","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/tyra-biosciences-announces-late-breaking-poster-presentation-on-tyra-300-preclinical-results-at-endo-2025\/"},"author":{"name":"Newsdesk","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"headline":"Tyra Biosciences Announces Late-Breaking Poster Presentation on TYRA-300 Preclinical Results at ENDO 2025","datePublished":"2025-07-08T20:20:13+00:00","mainEntityOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/tyra-biosciences-announces-late-breaking-poster-presentation-on-tyra-300-preclinical-results-at-endo-2025\/"},"wordCount":464,"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/tyra-biosciences-announces-late-breaking-poster-presentation-on-tyra-300-preclinical-results-at-endo-2025\/#primaryimage"},"thumbnailUrl":"https:\/\/mma.prnewswire.com\/media\/1626125\/Tyra_Logo.jpg","inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/tyra-biosciences-announces-late-breaking-poster-presentation-on-tyra-300-preclinical-results-at-endo-2025\/","url":"https:\/\/www.marketnewsdesk.com\/index.php\/tyra-biosciences-announces-late-breaking-poster-presentation-on-tyra-300-preclinical-results-at-endo-2025\/","name":"Tyra Biosciences Announces Late-Breaking Poster Presentation on TYRA-300 Preclinical Results at ENDO 2025 - Market Newsdesk","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/tyra-biosciences-announces-late-breaking-poster-presentation-on-tyra-300-preclinical-results-at-endo-2025\/#primaryimage"},"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/tyra-biosciences-announces-late-breaking-poster-presentation-on-tyra-300-preclinical-results-at-endo-2025\/#primaryimage"},"thumbnailUrl":"https:\/\/mma.prnewswire.com\/media\/1626125\/Tyra_Logo.jpg","datePublished":"2025-07-08T20:20:13+00:00","author":{"@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"breadcrumb":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/tyra-biosciences-announces-late-breaking-poster-presentation-on-tyra-300-preclinical-results-at-endo-2025\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.marketnewsdesk.com\/index.php\/tyra-biosciences-announces-late-breaking-poster-presentation-on-tyra-300-preclinical-results-at-endo-2025\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/tyra-biosciences-announces-late-breaking-poster-presentation-on-tyra-300-preclinical-results-at-endo-2025\/#primaryimage","url":"https:\/\/mma.prnewswire.com\/media\/1626125\/Tyra_Logo.jpg","contentUrl":"https:\/\/mma.prnewswire.com\/media\/1626125\/Tyra_Logo.jpg"},{"@type":"BreadcrumbList","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/tyra-biosciences-announces-late-breaking-poster-presentation-on-tyra-300-preclinical-results-at-endo-2025\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/www.marketnewsdesk.com\/"},{"@type":"ListItem","position":2,"name":"Tyra Biosciences Announces Late-Breaking Poster Presentation on TYRA-300 Preclinical Results at ENDO 2025"}]},{"@type":"WebSite","@id":"https:\/\/www.marketnewsdesk.com\/#website","url":"https:\/\/www.marketnewsdesk.com\/","name":"Market Newsdesk","description":"Latest Business News in Real Time","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.marketnewsdesk.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979","name":"Newsdesk","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","caption":"Newsdesk"},"url":"https:\/\/www.marketnewsdesk.com\/index.php\/author\/newsdesk\/"}]}},"_links":{"self":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/867629","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/comments?post=867629"}],"version-history":[{"count":0,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/867629\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/media?parent=867629"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/categories?post=867629"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/tags?post=867629"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}